Shorla enters deal to license chemotherapy drug in US
07 Jul 2023
License out/inDrug Approval
Preview
Source: Pharmaceutical Technology
PIP-101 is claimed to reduce or hinder the growth of some types of leukaemia. Credit: Ed Uthman / Flickr (Creative Commons).
Shorla Oncology has signed a licensing agreement and strategic collaboration with an undisclosed drug development and production firm in the UK for a chemotherapy drug, PIP-101.
Shorla will obtain a licence from the UK company to register and market the drug in the US.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Desidustat in Chemotherapy Induced Anemia GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Sulanemadlin in Chemotherapy Induced Myelosuppression GlobalData
View allCompanies IntelligenceShorla Pharma LtdView all
PIP-101 is an oral solution that reduces or hinders the growth of some types of leukaemia, including chronic myeloid leukaemia and acute lymphoblastic leukaemia.
The developer will produce PIP-101 and once Shorla receives a new drug application clearance, it will oversee the launch, marketing and sales of the drug in the US.
Shorla Oncology CEO and co-founder Sharon Cunningham stated: “We are excited to partner with and leverage the developer’s oral oncology liquid manufacturing expertise.
“This commercial partnership is a strong endorsement of our commitment to bring to market differentiated oncology treatments to address key areas of unmet needs for patients.”
In March 2023, the company received approval from the US Food and Drug Administration for its Nelarabine injection to treat T-cell leukaemia.
The company is partnering with Eversana to launch this injection commercially.
By the end of 2024, Shorla anticipates making its three products available in the market and having at least three further products at a developmental stage.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.